LBRX vs XENE
LBRX: LB Pharmaceuticals is a late-stage biopharmaceutical firm developing LB-102, a novel benzamide candidate aimed at becoming a first-in-class treatment for schizophrenia and mood disorders in the U.S. market. XENE: A pre-commercial neuroscience biotech racing to bring azetukalner, a differentiated potassium channel opener, through Phase 3 trials for epilepsy and depression.
Side-by-side fundamentals
| Metric | LBRX | XENE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $35.84 | $66.18 | |
| Market cap as of 2026-07-23 | $921M | $6.7B | |
| PEG as of 2026-07-23 | n/a | -0.30 | |
| Net margin as of 2026-07-23 | n/a | -867.3% | |
| Operating margin as of 2026-07-23 | n/a | -969.8% | |
| ROE as of 2026-07-23 | -17.7% | -49.2% | LBRX higher |
| ROA as of 2026-07-23 | -16.9% | -46.4% | LBRX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -7.3% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -77.8% | |
| Beta as of 2026-07-23 | 1.30 | 0.63 | |
| 1-year return as of 2026-07-22 close | +45.1% | +111.2% | XENE higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.